Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to ...

Total revenue of $218 million to $222 million (approximately 24% to 26% growth year-over-year) Non-GAAP gross margin of 80% to 81% “Our strong fourth quarter performance concluded a record year for ...

Change Change 4Q25 vs 3Q25 2025 vs 2024 Cash flow from operations excluding working capital (CFFO)(1) (B$) 7.2 +2% 27.8 -7% Adjusted net income (TotalEnergies share)(1) - in billions of dollars (B$) 3 ...

ATHENS, Greece, March 04, 2026 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (PSHG) (“we” or the “Company”), a global shipping company specializing in the ownership of tanker vessels, today reported ...

Operating profit for the fourth quarter of fiscal 2025 increased 106.1% to $606.3 million compared to $294.2 million in the fourth quarter of fiscal 2024. In the fourth quarter of fiscal 2024, the ...

1JV Inkai EBITDA is included in the uranium segment. See Financial results by segment - Uranium in our 2025 annual MD&A. The following Westinghouse financial outlook for 2025 is reported in US dollars ...

Gross premiums written by the mortgage segment in the 2025 fourth quarter were 1.5% lower than in the 2024 fourth quarter, while net premiums written were 3.6% lower than in the 2024 fourth quarter.

Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14, 2026 Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and ...